ACTIVE HYDRAULIC VENTRICULAR ATTACHING SUPPORT SYSTEM
Technical description of this US patent
Technical Problem to be Solved by the Present Invention With respect to the passivity and uniqueness of the conventional CSD technology, the present invention provides an active hydraulic ventricular attaching support system, which produces direct support effect to various heart diseases by mounting on an outer wall of ventricle. The present invention further provides active physical treating effect capable of controlling the pressure and rhythm. The active hydraulic ventricular attaching support system is connected with an administration system to further provide medicine treating effect.
Technical Proposal
Accordingly, in order to accomplish the above objects, the present invention provides an active hydraulic ventricular attaching support system, comprising:
a net cover fbr surrounding a ventricle, formed by hollow tubes, wherein all the hollow tubes are communicated with each other or form several independent areas, wherein the hollow tubes are communicated with each other within the areas while the areas are not communicated with each other.
The net cover structure formed by the tubes structure is mounted on a heart as an entirety. The hollow tubes structure can be filled various fluids of different physical characters. The fluids produce corresponding reactive pressure with respect to the heart action, effecting on the ventricle. The pressure produced by the passive expansion of the tubular net cover is applied on the heart through constriction of the heart.
A method of transplanting the tube-net structure is similar to the transplantation of the CSD. The basic steps thereof comprises: sleeving the tube-net structure structure onto the ventricle, interruptedly suturing an upper edge thereof with atrioventricular groove, and then suturing the tube-net structure in front of the heart in linear according to fitness of the tube-net structure, which should not be too tight, so as to avoid acute restrictive heart dysfunction, wherein decreasing of LVEDD (left ventricular end-diastolic dimension) caused by suturing should be within 10%.
A plurality of apertures are provided on a surface of the hollow tubes forming the net cover, wherein the surface attaches to the ventricular wall. Without the apertures, the system can only provide active hydraulic ventricular attaching and supporting function. But with the apertures, the system can provide not only active hydraulic ventricular attaching and supporting function, but also administrating function. Accordingly, the medicine compound or embryonic stem cell or bone marrow stem cell in the fluid inside the tubes can effect on cardiac muscle directly, and produce direct pharmacological action under high local concentration on cardiac muscle or other heart tissues without entering blood circulation.
No matter with or without the apertures, the net cover has two or more ends connected to an exterior of body, and each of the independent areas forming the net cover has two or more ends connected to the exterior of body. The ends connected to the exterior of body are connected with a main body of the net cover by seamless and integrated tubules which are communicated with the tubes system of the main body of the net cover integratedly and can be filled with various fluids. Additionally, the tubules may have same or different material with the main body of the net cover, and same or different diameter with the main body of the net cover. The ends connected to the exterior of body can be round, elliptic, square, or other shapes, which are only limited to connecting with instruments or equipments outside the body with good sealing and firmly connection, so as to avoid any gap or hole, any leaking of gas or fluid inside the tubes, or entering of external fluid, gas, solid or microorganism into the tubes. For realizing basic hydraulic function, each independent area has at least two ends connected with the exterior of body and forming a through way. Therefore, a pressure determined outside the body can be transferred to the ventricle via the fluid inside the tubes, and applies stronger and adjustable restriction effect. Through connecting to the exterior ofbody, the ends can be further connected with a force pump, which can adjust the pressure of the fluid better.
The net cover with the apertures, can be connected with an administrating system outside the body via the ends connected with the exterior of body. Therefore, medicine from outside can fill and spread all over the net cover, and then apply on the ventricle via the apertures. Accordingly, the species, concentration, and dose of medicine, and speed of administration can be adjusted outside the body, which applies to the heart tissues quickly via the device provided by the present invention.
A membrane can be attached outside the apertures, having selective permeability that selectively allows medicine molecules of certain size, weight, electric quantity, or molecular configuration, so as to further control the species, dose and speed of administration.
When the diameter of the apertures is not larger than a half of the diameter of the hollow tube, the hollow tube performs best. And if the diameter of the apertures is too large, the effect of the hollow tubes will be reduced. Particularly, the diameter of the hollow tubes is 1 -2 mm, wherein the diameter of the apertures is 0.5-1.0 mm.
The hollow tubes are made by a flexible material selected from the group consisting of rubber, silica gel, silicone, and other materials of macromolecule and flexible physical character, and especially, selected from nanophase materials capable of loading a medicine.
When the net cover is divided into the several areas, the hollow tubes dividing the areas can have an equal or larger diameter than the rest hollow tubes, i.e., 0.5-2 mm.
A wall of the tubes can be made by nanophase materials capable of loading a medicine, and thus are capable of releasing the medicine.
The net cover is made by gridding formed by tubes in appearance. Before sleeving the ventricle, the density of the gridding is 50-100 per square centimetre on surface, which can also be adjusted according to production process and clinical requirement. It is worth mentioning that, once the net cover is transplanted onto the surface of the heart, the net cover will expands fbr a certain degree. Therefore, the density of the gridding will change, generally, to be less than that just produced.
Beneficial Effect of this US patent
The present invention provides an active hydraulic ventricular attaching support system which has not only treatment effect of the CSD but also active controllable hydraulic support effect, and further composition effect by combined with local administration. The above effects produce active, positive, and synthetical treatment and restriction effect to stable myocardial ischemia, unstable myocardial ischemia, myocardial infarction, primary organic arrhythmia, expansionary heart diseases, and especially expansionary ventricle of patients of end-staged heart failure, and can be used to treat the above diseases.
The paticular effects are as follows.
Due to the evenness of fluid pressure in the basic structure of the present invention, the device provides more even, lasting, relaxative and stable restriction to the ventricle.
The hollow tubes forming the net cover have the apertures on the wall thereof attaching to the ventricle. Various kinds of fluids are filled inside the tubes. The fluids comprise various medical components, or embryonic stem cells or bone marrow stem cells. Duo to the existing of the apertures, the medicine can directly apply on the cardiac muscle or other heart tissues without entering blood circulation. Therefore, even some medicines which are quite toxic to other organs or tissues of the body but are good to the heart diseases, can also be used without worrying about the toxicity to other organs or tissues. Because the medicines take effect through applying to the heart directly without entering blood circulation, the toxicity to other organs or tissues will not be produced. Accordingly, based on the same reason, the medicine concentration inside the tubes can be very high without worrying about the untoward effect to other organs or tissues. Therefore, under high local concentration, the medicine can produce large direct pharmacological action to the heart, which is obviously better than systemic administration.
No matter with or without the apertures, the net cover has two or more ends connected to an exterior of body, and each of the independent areas forming the net cover has two or more ends connected to the exterior of body. Therefore, a pressure determined outside the body can be transferred to the ventricle via the fluid inside the tubes, and applies stronger and adjustable restriction effect to the ventricle. Through connecting to the exterior of body, the ends can be further connected with a force pump, which can adjust the pressure of the fluid better.
The net cover with the apertures, can be connected with an administrating system outside the body via the ends connected with the exterior of body. Therefore, medicine from outside can spread all over the net cover or concentrate on an independent area of the net cover via the hollow tubes, and then apply on the ventricle via the apertures. Accordingly, the species, dose, and concentration of medicine, time and period of administration, and even the whole administration proposal can be adjusted optionally at any time, so as to have controlling in treatment and further increase the treatment effect.
A membrane can be attached outside the apertures, having selective permeability that selectively allows medicine molecules of certain size, weight, electric quantity, or molecular configuration in a certain speed or flow rate, so as to control the species, size, structure, permeation speed and permeation flow rate of the medicine molecules applying on the heart, and further control the species, dose and spreading speed of the medicine in the heart tissue, and still further help the safety, controlling, effect and economy of clinical administration.
When the diameter of the apertures is not larger than a half of the diameter of the hollow tube, the hollow tube performs best. And if the diameter of the apertures is too large, the effect of the hollow tubes will be reduced. Particularly, the diameter of the hollow tubes is 1 -2 mm, wherein the diameter of the apertures is 0.5-1.0 mm. Tubes of diameter within this scope have good support effect to the heart wall, good hydraulic reactivity, and good permeation efficiency to the heart tissue fbr the medicine.
The hollow tubes are made by a flexible material, so as to make sure that the tubes filled with the fluids have good capacity and flexibility, so as to ensure good hydraulic reactivity fbr the expected hydraulic ventricle support effect.
The tube wall can adopt nanophase materials capable of loading a medicine. Only if the tube wall materials combine with medicine, the net cover will produce medical treatment effect, so as to combine with the heart wall support effect.
This US patent accepts the following approaches to cooperation:
Technology licensing
Technology investment shares